FBRX FORTE BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, FORTE BIOSCIENCES INC reported revenue of n/a, net income of −$23.3M and diluted EPS of −$0.97; for the fiscal year ended December 2025 revenue was n/a.
FBRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$70.7M, net income −$69.4M (margin n/a), EPS −$4.71
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$36.6M, net income −$35.5M (margin n/a), EPS −$12.17
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$32.5M, net income −$31.5M (margin n/a), EPS −$24.92
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$13.9M, net income −$13.9M (margin n/a), EPS −$0.80
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$21.5M, net income −$21.7M (margin n/a), EPS −$1.55
FBRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$23.3M, EPS −$0.97
- Quarter ended Mar 31, 2026: revenue n/a, net income −$22.1M, EPS −$1.24
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$24.8M, EPS −$1.39
- Quarter ended Sep 30, 2025: revenue n/a, net income −$17.7M, EPS −$0.99
- Quarter ended Jun 30, 2025: revenue n/a, net income −$11.2M, EPS −$0.96
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.7M, EPS −$1.37
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$7.16M, EPS $3.18
- Quarter ended Sep 30, 2024: revenue n/a, net income −$8.39M, EPS −$4.54
- Quarter ended Jun 30, 2024: revenue n/a, net income −$12.5M, EPS −$6.78
- Quarter ended Mar 31, 2024: revenue n/a, net income −$7.42M, EPS −$4.03
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.87M, EPS −$17.61
- Quarter ended Sep 30, 2023: revenue n/a, net income −$9.96M, EPS −$6.57
- Quarter ended Jun 30, 2023: revenue n/a, net income −$8.90M, EPS −$0.42
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.75M, EPS −$0.32
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$4.88M, EPS −$0.24
- Quarter ended Sep 30, 2022: revenue n/a, net income −$3.40M, EPS −$0.18
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.04M, EPS −$0.21
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.57M, EPS −$0.17
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$3.34M, EPS −$0.22
- Quarter ended Sep 30, 2021: revenue n/a, net income −$7.75M, EPS −$0.54
FBRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$50.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$30.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$28.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$8.19M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$16.7M, share buybacks n/a
FBRX balance sheet
- Jun 30, 2026: cash $49.6M, total assets $206M, total liabilities $21.9M, shareholders' equity $184M
- Mar 31, 2026: cash $58.2M, total assets $67.2M, total liabilities $25.1M, shareholders' equity $42.1M
- Dec 31, 2025: cash $77.0M, total assets $82.8M, total liabilities $21.8M, shareholders' equity $61.0M
- Sep 30, 2025: cash $93.4M, total assets $97.1M, total liabilities n/a, shareholders' equity $84.1M
- Jun 30, 2025: cash $106M, total assets $108M, total liabilities n/a, shareholders' equity $98.6M
- Mar 31, 2025: cash $45.9M, total assets $47.5M, total liabilities n/a, shareholders' equity $38.4M
- Dec 31, 2024: cash $22.2M, total assets $61.6M, total liabilities $9.08M, shareholders' equity $52.5M
- Sep 30, 2024: cash $16.4M, total assets $17.9M, total liabilities n/a, shareholders' equity $9.37M
Is FBRX profitable?
No. FORTE BIOSCIENCES INC lost $87.9M over the last four quarters.
What is FBRX's EPS?
Diluted earnings per share over the last four quarters were −$4.59; −$0.97 in the latest quarter.